On-Pump Coronary Artery Bypass Device Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: ONCAB Disposable and Perfusion System Market

Global On-Pump Coronary Artery Bypass Device Market Report to 2032

The global on-pump coronary artery bypass device market was valued at $583.3 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 3.0%, reaching $719.6 million by 2032.

This report covers the global market for on-pump coronary artery bypass (ONCAB) devices, including disposable kits and perfusion system devices used during CABG procedures.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by continued ONCAB procedural preference and improved cardiopulmonary bypass technologies. However, CABG procedure moderation, ONCAB-related side effects, and alternatives such as PCI, OPCAB, and ECMO are expected to limit stronger expansion.

Market Overview

The global on-pump coronary artery bypass device market includes products used during coronary artery bypass grafting procedures performed with cardiopulmonary bypass support. These devices help maintain circulation and oxygenation while the heart is stopped, allowing surgeons to operate in a motionless and bloodless field.

The market includes ONCAB disposables and perfusion systems. Disposable products include procedure kits, tubing sets, filters, oxygenators, and related components, while perfusion systems include capital equipment used to support extracorporeal circulation.

The global volume of CABG procedures has declined in recent years as less invasive interventional alternatives have gained traction. Catheter-based approaches can offer shorter hospital stays and faster recovery than traditional open-heart surgery, which has shifted treatment patterns in some patient groups.

Despite this pressure, ONCAB remains important for complex or high-risk coronary patients who require surgical revascularization. As a result, the market is expected to grow modestly through 2032, supported by continued procedural use, technology upgrades, and demand for reliable perfusion support.

Market Drivers

ONCAB Procedural Preference

CABG procedures can be performed on-pump or off-pump. Off-pump techniques were developed over a decade ago, and it was initially thought that OPCAB procedures could eventually overtake ONCAB as the surgical standard.

However, adoption of OPCAB has been limited because of the technical difficulty involved. Many surgeons remain hesitant or resistant to adopting more difficult off-pump techniques, especially in complex cases.

ONCAB is expected to remain the surgical standard for CABG procedures. By redirecting blood flow to a pump, surgeons can clamp the aorta and stop the heart, creating a motionless and bloodless surgical field. This allows precise graft suturing and consistent, reproducible outcomes.

Precision and Surgical Control

The ability to operate on a still heart remains one of the strongest clinical advantages of ONCAB. During on-pump procedures, surgeons can create precise connections between the graft vessel and the aorta while effectively bypassing narrowed or obstructed coronary arteries.

The absence of blood flow and heart motion helps support procedural accuracy. This is especially important in patients with complex coronary anatomy or multiple-vessel disease.

Because precision and control remain central to CABG success, ONCAB techniques continue to be preferred by many cardiac surgeons. This procedural preference supports ongoing demand for perfusion systems and ONCAB disposables.

New and Improved Technologies

Cardiopulmonary bypass technology is relatively mature compared with many newer medical device areas, but manufacturers continue to improve the safety and performance of ONCAB products.

Companies in the perfusion system market have worked to reduce the negative effects of extracorporeal circulation through better system design, monitoring, and more biocompatible materials.

Heparin-coated oxygenators and other biocompatible surfaces are designed to better mimic the vascular endothelium. These technologies may help reduce systemic inflammation and lower the tendency for blood to clot in the CPB circuit. These improvements support surgeon and patient confidence in ONCAB procedures.

Market Limiters

CABG Procedure Moderation

CABG procedure moderation is a major limiter for the ONCAB device market. Advancements in PCI technology are expected to keep CABG volumes relatively flat over the forecast period.

The value of the ONCAB market is directly tied to the number of CABG procedures performed each year. If procedure volume does not grow strongly, the market has limited opportunity for expansion.

There are also few major technological innovations or reimbursement changes that would allow manufacturers to raise ASPs meaningfully. As a result, procedure volume remains the primary growth lever, and flat CABG volumes are expected to keep market growth limited.

ONCAB Negative Side Effects

ONCAB procedures require a cardiopulmonary bypass pump, which exposes the patient's blood to foreign surfaces. This has been associated with increased bleeding risk and short-term neurocognitive effects.

These effects are often described as post-perfusion syndrome, or "pump head." Symptoms can include issues with attention, concentration, short-term memory, fine motor function, and the speed of mental and motor responses.

Stopping the heart may also impair or damage the heart muscle. In addition, clamping the aorta has been shown in some studies to release thrombogenic agents that may contribute to strokes. These concerns have encouraged some surgeons to transition toward off-pump and minimally invasive CABG techniques.

Alternatives

Alternative treatment options continue to limit ONCAB market growth. PCI technology has advanced significantly and can reduce the need for surgical revascularization in some patients.

OPCAB is also a direct alternative to ONCAB. Although it has not replaced ONCAB as the surgical standard, it remains available for selected patients and surgeons who prefer off-pump approaches.

ECMO is another alternative to heart-lung machines in certain clinical settings. ECMO is growing faster than the ONCAB market and may compete for investment, attention, and procedural use in specific patient populations.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers on-pump coronary artery bypass devices, including ONCAB disposables and perfusion system devices used to support cardiopulmonary bypass during CABG procedures.

Markets Covered and Segmentation

On-Pump Coronary Artery Bypass Device Market

• Device type: ONCAB disposables and perfusion systems.

ONCAB disposables include single-use components used during cardiopulmonary bypass procedures. These may include cardiovascular procedure kits, tubing sets, cardioplegia components, arterial filters, oxygenators, and other disposable perfusion products used during CABG.

Perfusion systems include capital equipment used to maintain circulation and oxygenation while the heart is stopped. These systems are central to the ONCAB workflow and are supported by continued upgrades in monitoring, integration, and procedural control.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how procedure volume, disposable utilization, perfusion system upgrades, surgeon preference, and competition from alternative revascularization methods are shaping the global ONCAB market.

Competitive Analysis

LivaNova was the leading competitor in the global ONCAB market in 2025, with strong leadership across both the perfusion system and disposable segments. The company has continued to invest in ONCAB innovation, including the launch and geographic expansion of its Essenz(TM) Perfusion System.

The Essenz(TM) Perfusion System was introduced into the Chinese market in 2025 and includes enhanced real-time monitoring and system integration capabilities. Supported by its broad product portfolio, installed base, and ongoing platform upgrades, LivaNova is well positioned to maintain and potentially expand its market share.

Terumo was the second-leading competitor in the ONCAB market in 2025. The company offers its Prestige Pack(TM) cardiovascular procedure kit as its disposable kit option, along with the CAPIOX(R) and Sarns(TM) lines of disposable perfusion products.

Due to the presence of regional companies rising in popularity, Terumo is expected to maintain its current market share over the coming years rather than gain significant share.

Medtronic was the third-leading competitor in the ONCAB market in 2025. The company offers tubing sets, cardioplegia products, and arterial filters as disposable kit components. Medtronic has also developed biocompatible surfaces with heparin-coated oxygenators, including Cortiva(R) and Trillium(R) bioactive surfaces.

Technology and Practice Trends

Perfusion System Upgrades

Perfusion system upgrades remain an important technology trend in the ONCAB market. Although CPB technology is mature, manufacturers continue to improve monitoring, integration, and workflow support.

Newer systems are designed to give perfusion teams better real-time information during procedures.

Biocompatible Surfaces

Biocompatible surfaces are being developed to reduce the negative effects of extracorporeal circulation. Heparin-coated oxygenators are designed to better mimic the vascular endothelium.

These surfaces may help reduce inflammation and decrease clotting risk within the CPB circuit.

Continued ONCAB Standardization

ONCAB remains the standard approach for many CABG procedures because it provides a stable and controlled surgical environment.

This supports continued use of perfusion systems and disposables, even as less invasive alternatives gain adoption.

Pressure from PCI

Advancements in PCI are moderating CABG procedure volumes. As interventional cardiology continues to improve, some patients who may have previously undergone CABG can be treated with less invasive approaches.

This trend will continue to affect ONCAB demand.

Off-Pump and Minimally Invasive CABG

OPCAB and minimally invasive CABG techniques remain alternatives to ONCAB. Although adoption is limited by technical difficulty, these approaches can reduce some risks associated with cardiopulmonary bypass.

Surgeon experience and patient selection will continue to shape their use.

ECMO Growth

ECMO is growing faster than the ONCAB market and serves as an alternative to heart-lung machines in certain settings.

Its expansion reflects broader demand for advanced cardiopulmonary support technologies and may influence investment priorities across cardiac surgery and critical care.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global on-pump coronary artery bypass device market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• What role do ONCAB disposables and perfusion systems play in CABG procedures?
• Why does ONCAB remain the surgical standard for many CABG procedures?
• How are PCI advancements moderating CABG procedure volumes?
• How do ONCAB side effects affect surgeon preference and procedural selection?
• What role do biocompatible surfaces and improved perfusion systems play in market development?
• How are OPCAB, minimally invasive CABG, and ECMO affecting the ONCAB market?
• Which companies lead the global ONCAB device market?
• How are LivaNova, Terumo, and Medtronic positioned in the competitive landscape?

The Global On-Pump Coronary Artery Bypass Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand CABG technology trends, and support commercial planning in the global ONCAB market.